IQVIA Holdings Inc. (IQV) Intrinsic Value & DCF Valuation
Medical - Diagnostics & Research · NYSE
Current Price
$259.82
Intrinsic Value
$295.27
+12.0% margin of safety
What Is IQVIA Holdings Inc.'s Intrinsic Value?
As of 2026-08-21, the base-case DCF model estimates the intrinsic value of IQVIA Holdings Inc. (IQV) at $295.27 per share, compared with a market price of $259.82, a margin of safety of +12.0%. The base case assumes 6.7% annual free cash flow growth and a 10.0% discount rate.
Across the sensitivity grid the estimate spans $234.11 to $365.86. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.
How the DCF works · Recalculate with your own assumptions · What is intrinsic value?
Is IQVIA Holdings Inc. (IQV) Undervalued?
At $259.82, IQV trades about 12.0% below the base-case intrinsic value estimate. That is a real discount, but it stays short of the 30% margin of safety required before calling a stock undervalued.
COMPETITIVE MOAT
INVESTMENT RISKS
Base case
IQV base case valuation
Intrinsic Value
$295.27
Margin of safety
+12.0%
Expected annual return
+2.6%
Base case assumptions: 6.7% annual growth, 10.0% discount rate, 16.37x exit multiple, 5 year projection. Data as of 2026-08-21.
This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Customize the IQV valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for IQVIA Holdings Inc. respond.
Open DCF Calculator for IQVCompany Overview
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Financial Metrics — IQV Stock Valuation Data
Revenue/Share (TTM)
$101.57
FCF/Share (TTM)
$15.63
ROIC (TTM)
8.3%
ROE (TTM)
22.0%
P/FCF
16.4x
EV/EBITDA
16.2x
FCF Yield
6.11%
Debt/Equity
2.63x
Based on trailing twelve-month data, IQV shows a free cash flow per share of $15.63 and a ROIC of 8.3%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 16.4x and FCF yield of 6.11% are important context metrics when evaluating IQV's stock valuation relative to peers.
Frequently Asked Questions
What is the intrinsic value of IQV?
IQVIA Holdings Inc. currently generates $15.63 in free cash flow per share. At the current price of $259.82, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is IQV undervalued?
IQV trades at a P/FCF ratio of 16.4x with a free cash flow yield of 6.11%. This P/FCF is in a moderate range. However, whether IQV is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.
How do I value IQV stock using DCF?
To perform a DCF valuation on IQVIA Holdings Inc.: (1) Start with the trailing free cash flow per share ($15.63) as the base, (2) project future FCF growth over 5-10 years based on Medical - Diagnostics & Research industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting IQV's risk profile — with a debt-to-equity of 2.63x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to IQV?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For IQVIA Holdings Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Diagnostics & Research trends, then discounting those amounts to today's dollars. IQV's ROIC of 8.3% shows moderate capital returns.
How does WACC affect IQV stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For IQV, with a debt-to-equity ratio of 2.63x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 16.2x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See IQV PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value IQV with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2026-08-21. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.